SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.

Results from the CCLE cell lines showed a tendency of decreased SETBP1 expression in the SETBP1 mutant group in both melanoma and NSCLC, although it did not reach statistical significance (Wilcoxon rank-sum test P = 0.068 and 0.153 for melanoma and NSCLC, respectively; Supplementary Figure 9A , 9B ).

also in 111,027 other papers